Page last updated: 2024-08-18

pyrazolanthrone and dinaciclib

pyrazolanthrone has been researched along with dinaciclib in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Mackey, ZB; Ramsey, AC; Santos, WL; Valenciano, AL	1
Caballero, E; García-Cárceles, J; Gil, C; Martínez, A	1
Bates, DJ; Eastman, A; Lowrey, CH; Salerni, BL	1

Reviews

1 review(s) available for pyrazolanthrone and dinaciclib

Article	Year
Kinase Inhibitors as Underexplored Antiviral Agents. Journal of medicinal chemistry, 2022, 01-27, Volume: 65, Issue:2 Topics: Animals; Antiviral Agents; Drug Repositioning; Humans; Protein Kinase Inhibitors; Virus Diseases; Viruses	2022

Other Studies

2 other study(ies) available for pyrazolanthrone and dinaciclib

Article	Year
Discovery and antiparasitic activity of AZ960 as a Trypanosoma brucei ERK8 inhibitor. Bioorganic & medicinal chemistry, 2016, 10-01, Volume: 24, Issue:19 Topics: Aminopyridines; Drug Discovery; Extracellular Signal-Regulated MAP Kinases; Humans; Protein Kinase Inhibitors; Pyrazoles; Recombinant Proteins; Trypanocidal Agents; Trypanosoma brucei brucei; Trypanosomiasis, African	2016
Vinblastine sensitizes leukemia cells to cyclin-dependent kinase inhibitors, inducing acute cell cycle phase-independent apoptosis. Cancer biology & therapy, 2011, Aug-15, Volume: 12, Issue:4 Topics: Anthracenes; Antineoplastic Agents, Phytogenic; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle; Cell Line, Tumor; Cell Survival; Cyclic N-Oxides; Cyclin-Dependent Kinase 9; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Drug Synergism; Flavonoids; HL-60 Cells; Humans; Immunoblotting; Indolizines; JNK Mitogen-Activated Protein Kinases; Jurkat Cells; Myeloid Cell Leukemia Sequence 1 Protein; Paclitaxel; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyridinium Compounds; U937 Cells; Vinblastine	2011

Article

Year

Discovery and antiparasitic activity of AZ960 as a Trypanosoma brucei ERK8 inhibitor.

Bioorganic & medicinal chemistry, 2016, 10-01, Volume: 24, Issue:19

Topics: Aminopyridines; Drug Discovery; Extracellular Signal-Regulated MAP Kinases; Humans; Protein Kinase Inhibitors; Pyrazoles; Recombinant Proteins; Trypanocidal Agents; Trypanosoma brucei brucei; Trypanosomiasis, African

2016

Vinblastine sensitizes leukemia cells to cyclin-dependent kinase inhibitors, inducing acute cell cycle phase-independent apoptosis.

Cancer biology & therapy, 2011, Aug-15, Volume: 12, Issue:4

Topics: Anthracenes; Antineoplastic Agents, Phytogenic; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle; Cell Line, Tumor; Cell Survival; Cyclic N-Oxides; Cyclin-Dependent Kinase 9; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Drug Synergism; Flavonoids; HL-60 Cells; Humans; Immunoblotting; Indolizines; JNK Mitogen-Activated Protein Kinases; Jurkat Cells; Myeloid Cell Leukemia Sequence 1 Protein; Paclitaxel; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyridinium Compounds; U937 Cells; Vinblastine

2011